Thrombophilia

Summary

Thrombophilia (MONDO:0002305) is a disease caused by variants in FGA, FGB, and FGG, with 3 cohort genes (33 GWAS associations across 10 studies) and 36 clinical trials. The dominant Reactome pathway is Aggregated β-amyloid interacts with fibrinogen (3 cohort genes). Top therapeutic interventions include dalteparin sodium, alteplase, and estradiol.

At a glance

• Causal genes: FGA (GenCC Strong), FGB (GenCC Strong), FGG (GenCC Strong)
• Cohort genes: 3
• GWAS associations: 33
• ClinVar variants: 1
• Clinical trials: 36

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	thrombophilia
Mondo ID	MONDO:0002305
EFO	EFO:0009315
MeSH	D019851
Orphanet	64738
DOID	DOID:2452
ICD-11	1733531851
NCIT	C84479
SNOMED CT	234467004
UMLS	C0398623
MedGen	98306
GARD	0023114
Is cancer (heuristic)	no

Also known as: excessive blood clotting · hypercoagulability · hypercoagulability state · hypercoagulable

Data availability: 1 ClinVar variant · 33 GWAS associations (10 studies) · 6 GenCC gene-disease records.

Disease family

An umbrella term covering 4 Mondo subtypes.

Classification path: disease › human disease › disease by body system or component › hematologic disorder › blood coagulation disease › thrombophilia

Related subtypes (7): marantic endocarditis, hemolytic-uremic syndrome, coagulation protein disease, hemorrhagic disease of newborn, thrombotic microangiopathy, inherited blood coagulation disorder, prekallikrein deficiency

Subtypes (4): disseminated intravascular coagulation, protein S deficiency, thrombotic thrombocytopenic purpura, inherited thrombophilia

Genetics & variants

GWAS landscape

33 GWAS associations across 10 studies. Top hits map to 9 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs145163454	1e-323	ATP1B1	T	2.21
rs77977611	1e-323	ATP1B1	T	1.77
rs1799963	3e-96	F2	G	1.33
rs115478735	6e-48	ABO	A	0.44
rs144737447	3e-24	NME7, ATP1B1	C	2.24
rs7654093	4e-16	FGG - LRAT	A	0.23
rs1894692	1e-14	SLC19A2 - F5	G	2.16
rs4253417	1e-14	F11	T	0.21
rs13130318	3e-14	FGG - LRAT	T	0.23
chr4:187187569	5e-13		G	0.21
rs192274652	7e-13	OR5BP1P - LRRC55	A	1.06
rs535555897	3e-12	ZNF160	T	3.09
rs572380810	7e-12	LINC01876	C	4.25
rs1003762587	1e-11	ELK1P1 - ADCY1	C	3.31
rs141687379	2e-11	FADS2B	A	0.96
rs181145115	2e-11	LINC02296 - LINC02330	A	2.23
rs557819020	3e-11	ATXN10 - WNT7B	C	2.37
rs145713571	4e-11	LINC02141 - NPAP1L	A	2.29
rs114856151	2e-08	WWOX	?

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90475802	Verma A	2024	2,636	447,006	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90475804	Verma A	2024	2,443	447,470	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90651565	Liu TY	2025	939	231,777	Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population.
GCST90651591	Liu TY	2025	916	231,777	Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population.
GCST90475801	Verma A	2024	578	120,902	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90479978	Verma A	2024	578	120,902	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90475803	Verma A	2024	522	121,041	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90479977	Verma A	2024	522	121,041	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90476488	Verma A	2024	200	59,565	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90727280	Kim HI	2026	134	43,892	Exome sequencing and analysis of 44,028 British South Asians enriched for high autozygosity.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	0
Tier 2: splice/UTR	1
Tier 3: regulatory	0
Tier 4: intronic/intergenic	18

MAF distribution

Bucket	Variants
common (>=0.05)	5
low_freq (0.01-0.05)	4
rare (<0.01)	9
unknown	1

Functional consequences

Consequence	Count
intron_variant	9
intergenic_variant	6
non_coding_transcript_exon_variant	2
3_prime_UTR_variant	1
unknown	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs145163454	1	169121510	T>A,C	0.023	intron_variant	ATP1B1	1e-323	Tier 4: intronic/intergenic
rs77977611	1	169112554	T>C,G	0.036	non_coding_transcript_exon_variant	ATP1B1	1e-323	Tier 4: intronic/intergenic
rs1799963	11	46739505	G>A	0.012	3_prime_UTR_variant	F2	3e-96	Tier 2: splice/UTR
rs115478735	9	133274295	A>T	0.158	intron_variant	ABO	6e-48	Tier 4: intronic/intergenic
rs144737447	1	169191220	C>T	0.004	intron_variant	NME7, ATP1B1	3e-24	Tier 4: intronic/intergenic
rs7654093	4	154623920	A>T	0.248	intergenic_variant	FGG - LRAT	4e-16	Tier 4: intronic/intergenic
rs1894692	1	169498416	G>A	0.022	non_coding_transcript_exon_variant	SLC19A2 - F5	1e-14	Tier 4: intronic/intergenic
rs4253417	4	186277851	T>C,G	0.345	intron_variant	F11	1e-14	Tier 4: intronic/intergenic
rs13130318	4	154617318	T>G	0.222	intergenic_variant	FGG - LRAT	3e-14	Tier 4: intronic/intergenic
chr4:187187569				0.387			5e-13	Tier 4: intronic/intergenic
rs192274652	11	57069003	A>G,T	0.004	intergenic_variant	OR5BP1P - LRRC55	7e-13	Tier 4: intronic/intergenic
rs535555897	19	53088515	T>C	0	intron_variant	ZNF160	3e-12	Tier 4: intronic/intergenic
rs572380810	2	156046828	C>A,T	0	intron_variant	LINC01876	7e-12	Tier 4: intronic/intergenic
rs1003762587	7	45434577	C>G,T	0	intron_variant	ELK1P1 - ADCY1	1e-11	Tier 4: intronic/intergenic
rs141687379	11	56899346	A>G	0.004	intron_variant	FADS2B	2e-11	Tier 4: intronic/intergenic
rs181145115	14	87584038	A>G	0	intergenic_variant	LINC02296 - LINC02330	2e-11	Tier 4: intronic/intergenic
rs557819020	22	45898102	C>T	0.002	intergenic_variant	ATXN10 - WNT7B	3e-11	Tier 4: intronic/intergenic
rs145713571	16	60117264	A>C,G	0.002	intergenic_variant	LINC02141 - NPAP1L	4e-11	Tier 4: intronic/intergenic
rs114856151	16	78893311	G>A		intron_variant	WWOX	2e-08	Tier 4: intronic/intergenic

ClinVar germline variants

1 retrieved; paginated sample, class counts are floors:

1 uncertain significance

ClinVar	Variant (HGVS)	Gene	Classification	Review
267918	46;XX;t(6;20)(q25.1;p13)dn		Uncertain significance	criteria provided, single submitter

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 29 · Orphanet: 13 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

Gene	Classification	Inheritance	Disease	Records
FGA	Strong	Autosomal dominant	thrombophilia	14
FGB	Strong	Autosomal dominant	thrombophilia	7
FGG	Strong	Autosomal dominant	thrombophilia	8

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
FGA	Orphanet:101041	Familial hypofibrinogenemia
FGA	Orphanet:248408	Familial hypodysfibrinogenemia
FGA	Orphanet:93562	AFib amyloidosis
FGA	Orphanet:98880	Familial afibrinogenemia
FGA	Orphanet:98881	Familial dysfibrinogenemia
FGB	Orphanet:101041	Familial hypofibrinogenemia
FGB	Orphanet:248408	Familial hypodysfibrinogenemia
FGB	Orphanet:98880	Familial afibrinogenemia
FGB	Orphanet:98881	Familial dysfibrinogenemia
FGG	Orphanet:101041	Familial hypofibrinogenemia
FGG	Orphanet:248408	Familial hypodysfibrinogenemia
FGG	Orphanet:98880	Familial afibrinogenemia
FGG	Orphanet:98881	Familial dysfibrinogenemia

Cohort genes → proteins

3 cohort genes, 3 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	3

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
FGA	HGNC:3661	ENSG00000171560	P02671	Fibrinogen alpha chain	gencc
FGB	HGNC:3662	ENSG00000171564	P02675	Fibrinogen beta chain	gencc
FGG	HGNC:3694	ENSG00000171557	P02679	Fibrinogen gamma chain	gencc

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
FGA	Fibrinogen alpha chain	Cleaved by the protease thrombin to yield monomers which, together with fibrinogen beta (FGB) and fibrinogen gamma (FGG), polymerize to form an insoluble fibrin matrix.
FGB	Fibrinogen beta chain	Cleaved by the protease thrombin to yield monomers which, together with fibrinogen alpha (FGA) and fibrinogen gamma (FGG), polymerize to form an insoluble fibrin matrix.
FGG	Fibrinogen gamma chain	Together with fibrinogen alpha (FGA) and fibrinogen beta (FGB), polymerizes to form an insoluble fibrin matrix.

Protein-family classification

Druggable: 0 · Difficult: 0 · Unknown: 3 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Other/Unknown	3	1.8×	0.174

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
FGA	Other/Unknown	no		Fibrinogen_a/b/g_C_dom, Fibrinogen_a/b/g_coil_dom, Fibrinogen_a/b/g_C_1
FGB	Other/Unknown	no		Fibrinogen_a/b/g_C_dom, Fibrinogen_a/b/g_coil_dom, Fibrinogen_a/b/g_C_1
FGG	Other/Unknown	no		Fibrinogen_a/b/g_C_dom, Fibrinogen_a/b/g_coil_dom, Fibrinogen_a/b/g_C_1

Expression context

Cohort genes with no expression data: 0.

3 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	3
unknown	0

Top tissues across cohort

Tissue	Cohort genes
liver	3
right lobe of liver	3
type B pancreatic cell	2
islet of Langerhans	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
FGA	153	tissue_specific	marker	right lobe of liver, liver, islet of Langerhans
FGB	159	broad	marker	right lobe of liver, liver, type B pancreatic cell
FGG	157	broad	marker	right lobe of liver, liver, type B pancreatic cell

Protein interactions among cohort

Intra-cohort edges: 3.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
FGB	2,503
FGA	2,327
FGG	2,018

Intra-cohort edges

A	B	Sources
FGA	FGB	intact, string_interaction
FGA	FGG	biogrid_interaction, intact, string_interaction
FGB	FGG	biogrid_interaction, string_interaction

Structural data

PDB: 3 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
FGG	P02679	47
FGB	P02675	41
FGA	P02671	39

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 22. Enrichment computed across 3 evidence-associated genes (3 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 3 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Aggregated β-amyloid interacts with fibrinogen	3	2855.0×	4e-10	FGA, FGB, FGG
Fibrin formation	3	878.5×	1e-08	FGA, FGB, FGG
p130Cas linkage to MAPK signaling for integrins	3	761.3×	1e-08	FGA, FGB, FGG
GRB2:SOS provides linkage to MAPK signaling for Integrins	3	713.8×	1e-08	FGA, FGB, FGG
MyD88 deficiency (TLR2/4)	3	601.0×	2e-08	FGA, FGB, FGG
IRAK4 deficiency (TLR2/4)	3	571.0×	2e-08	FGA, FGB, FGG
Regulation of TLR by endogenous ligand	3	496.5×	2e-08	FGA, FGB, FGG
Integrin signaling	3	423.0×	3e-08	FGA, FGB, FGG
Signaling by high-kinase activity BRAF mutants	3	317.2×	7e-08	FGA, FGB, FGG
MAP2K and MAPK activation	3	285.5×	9e-08	FGA, FGB, FGG
Signaling by RAF1 mutants	3	278.5×	9e-08	FGA, FGB, FGG
Signaling by moderate kinase activity BRAF mutants	3	253.8×	9e-08	FGA, FGB, FGG
Paradoxical activation of RAF signaling by kinase inactive BRAF	3	253.8×	9e-08	FGA, FGB, FGG
Signaling downstream of RAS mutants	3	253.8×	9e-08	FGA, FGB, FGG
Signaling by BRAF and RAF1 fusions	3	170.4×	3e-07	FGA, FGB, FGG
MyD88:MAL(TIRAP) cascade initiated on plasma membrane	3	152.3×	4e-07	FGA, FGB, FGG
Integrin cell surface interactions	3	134.3×	5e-07	FGA, FGB, FGG
ER-Phagosome pathway	3	129.8×	5e-07	FGA, FGB, FGG
Platelet degranulation	3	87.8×	2e-06	FGA, FGB, FGG
Post-translational protein phosphorylation	2	66.8×	3e-04	FGA, FGG
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)	2	57.7×	4e-04	FGA, FGG
Amyloid fiber formation	1	34.3×	0.029	FGA

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 3 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
blood coagulation, fibrin clot formation	3	1685.2×	2e-09	FGA, FGB, FGG
positive regulation of peptide hormone secretion	3	1532.0×	2e-09	FGA, FGB, FGG
plasminogen activation	3	1296.3×	2e-09	FGA, FGB, FGG
positive regulation of heterotypic cell-cell adhesion	3	1296.3×	2e-09	FGA, FGB, FGG
protein polymerization	3	991.3×	4e-09	FGA, FGB, FGG
fibrinolysis	3	842.6×	6e-09	FGA, FGB, FGG
positive regulation of vasoconstriction	3	601.9×	1e-08	FGA, FGB, FGG
positive regulation of exocytosis	3	601.9×	1e-08	FGA, FGB, FGG
negative regulation of extrinsic apoptotic signaling pathway via death domain receptors	3	581.1×	1e-08	FGA, FGB, FGG
negative regulation of endothelial cell apoptotic process	3	495.6×	2e-08	FGA, FGB, FGG
positive regulation of substrate adhesion-dependent cell spreading	3	374.5×	4e-08	FGA, FGB, FGG
positive regulation of protein secretion	3	343.9×	5e-08	FGA, FGB, FGG
platelet aggregation	3	337.0×	5e-08	FGA, FGB, FGG
response to calcium ion	3	318.0×	5e-08	FGA, FGB, FGG
cell-matrix adhesion	3	163.6×	4e-07	FGA, FGB, FGG
induction of bacterial agglutination	2	1872.4×	5e-07	FGA, FGB
protein-containing complex assembly	3	113.9×	9e-07	FGA, FGB, FGG
positive regulation of ERK1 and ERK2 cascade	3	85.1×	2e-06	FGA, FGB, FGG
blood coagulation, common pathway	1	2808.7×	4e-04	FGA
adaptive immune response	2	56.2×	5e-04	FGA, FGB
cellular response to leptin stimulus	1	510.7×	0.002	FGB
innate immune response	2	22.4×	0.003	FGA, FGB
cellular response to interleukin-1	1	93.6×	0.011	FGB
protein secretion	1	87.8×	0.011	FGG

Therapeutics

Drugs indicated for this disease

0 approved, 5 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Aspirin	Phase 3 (in late-stage trials)
Clopidogrel	Phase 3 (in late-stage trials)
Dalteparin Sodium	Phase 3 (in late-stage trials)
Nadroparin Calcium	Phase 3 (in late-stage trials)
Salicylic Acid	Phase 3 (in late-stage trials)

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 1 · Undrugged: 2

Druggability breadth: 3 of 3 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

Symbol	Molecules	Max phase
FGB	1	2
FGA	0	0
FGG	0	0

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
SANGUINARIUM	2	FGB

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
FGB	2	Binding:2

Pharmacogenomics

Cohort genes with a PharmGKB record: 3; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

1 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Compound	Max phase	Cohort target (bioactivity)
SANGUINARIUM	2	FGB

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	0
B	Phased (≥1) drug, not yet approved	1	FGB
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	2	FGA, FGG

Undrugged target profiles

2 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
FGA	0	FGB
FGG	0	FGB

Clinical trials & evidence

Clinical trials

Clinical trials: 36.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	30
PHASE3	3
PHASE4	2
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01214772	PHASE4	COMPLETED	The Effect of Heparin in Treatment IVF-ET Failure
NCT03531437	PHASE4	TERMINATED	Comparison of Coagulation Profiles Between Zoely and Minidoz: RCT
NCT06153394	PHASE3	NOT_YET_RECRUITING	Prolonged Hypercoagulability Following Major Liver Resection for Malignancy
NCT00967382	PHASE3	COMPLETED	TIPPS: Thrombophilia in Pregnancy Prophylaxis Study
NCT01046942	PHASE3	UNKNOWN	ThrombElastoGraphic Haemostatic Status and Antiplatelet Therapy After Coronary Artery Bypass Graft Surgery
NCT05540834	PHASE2	RECRUITING	Viscoelastic Testing Guided Tissue Plasminogen Activator Treatment in Acute Respiratory Failure
NCT04398628	Not specified	RECRUITING	ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
NCT04537416	Not specified	ACTIVE_NOT_RECRUITING	Fertility, Hypercoagulability, and Inflammation (FREYA) Registry
NCT05853796	Not specified	RECRUITING	Observational Dutch Young Symptomatic StrokE studY - nEXT
NCT06727669	Not specified	RECRUITING	Longitudinal Cohort of Thrombosis and Hemostasis Diseases
NCT07108023	Not specified	NOT_YET_RECRUITING	Hematological Disorders in EHPVO Patients
NCT07372170	Not specified	RECRUITING	Observational Study to Evaluate the Effectiveness of DOACS for Secondary Thrombosis Prevention in Low-risk Thrombotic APS Patients
NCT07571096	Not specified	RECRUITING	Construction of a Multi-dimensional Risk Assessment System: a Clinical Study of Polycystic Ovary Syndrome Complicated With Thrombophilia
NCT00354796	Not specified	UNKNOWN	The Effect of Reduced Dose of Enoxaparin on the Outcomes of Treatment With Enoxaparin
NCT00356434	Not specified	TERMINATED	A Comparison of Sequential Compression Devices and Foot Pumps in the Obstetric Population
NCT00457184	Not specified	COMPLETED	Thrombophilia and Migraine, Are They Related?
NCT00883272	Not specified	COMPLETED	Effect of DT56a (Femarelle) on the Coagulation System in the Treatment of Postmenopausal Women
NCT01160159	Not specified	TERMINATED	Arterial Microcirculation, Macrocirculation and Thrombophilias
NCT01372553	Not specified	COMPLETED	Guilford Genomic Medicine Initiative (GGMI)
NCT01416454	Not specified	COMPLETED	Thromboelastography to Assess Age-Related Coagulation Differences in Patients Undergoing Cesarean Delivery
NCT01486511	Not specified	UNKNOWN	Pulmonary Embolism After Liver Resection
NCT01487291	Not specified	COMPLETED	Prevalence of Clinical and Laboratory Markers of Hypofibrinolysis in Psychotic Patients
NCT01905748	Not specified	UNKNOWN	Acute Phase Reactions and Thrombophilia in Pediatric Patients With Migraine
NCT02139670	Not specified	COMPLETED	Thrombin Generation and Gestational Outcome
NCT02407730	Not specified	COMPLETED	EFFects of Thrombophilia on the Outcomes of Assisted Reproduction Technologies
NCT02701452	Not specified	TERMINATED	Ovarian Hyperstimulation Syndrome in Patients Triggered by GnRH Agonist for Excessive Follicular Response
NCT02718924	Not specified	COMPLETED	Detecting Hypercoagulability in Morbidly Obese and Non Obese Parturients Following Cesarean Section Delivery
NCT03682419	Not specified	COMPLETED	Evaluation of Precision and Accuracy of INR Measurements in a Point of Care Device (OPTIMAL)
NCT04059965	Not specified	WITHDRAWN	AntiCoagulation Tracking InterVention and Evaluation
NCT04393805	Not specified	COMPLETED	Heparins for Thromboprophylaxis in COVID-19 Patients: HETHICO Study in Veneto
NCT04503317	Not specified	COMPLETED	Effect of Phototherapy With Exercise on Coagulation in Elderly
NCT04519398	Not specified	UNKNOWN	Investigating the Involvement of ACE and Angiotensinogen Genes’ Polymorphism Along With Other Thrombophilic Genotypes in Severe Forms of COVID-19 With/Without Thrombotic Events
NCT04736901	Not specified	COMPLETED	Effect of Prophylactic and Therapeutic Anticoagulants in Egyptian Patients With COVID-19
NCT05225155	Not specified	COMPLETED	Effect of Prophylatic Use of Enoxaparin in Women Undergoing in Vitro Fertilization Treatment
NCT05551078	Not specified	UNKNOWN	Thrombophilia Screening After Severe IUGR
NCT06171984	Not specified	UNKNOWN	Thrombophilia Assessment Under DOAC: Effectiveness of Activated Charcoal

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
DALTEPARIN SODIUM	4	2
ALTEPLASE	4	1
ESTRADIOL	4	1
HEPARIN	4	1
CHEMBL4071896	0	1
CHEMBL4128407	0	1
CHEMBL5182436	0	1